TY  - GEN
AU  - Sax,Paul E
AU  - Wohl,David
AU  - Yin,Michael T
AU  - Post,Frank
AU  - DeJesus,Edwin
AU  - Saag,Michael
AU  - Pozniak,Anton
AU  - Thompson,Melanie
AU  - Podzamczer,Daniel
AU  - Molina,Jean Michel
AU  - Oka,Shinichi
AU  - Koenig,Ellen
AU  - Trottier,Benoit
AU  - Andrade-Villanueva,Jaime
AU  - Crofoot,Gordon
AU  - Custodio,Joseph M
AU  - Plummer,Andrew
AU  - Zhong,Lijie
AU  - Cao,Huyen
AU  - Martin,Hal
AU  - Callebaut,Christian
AU  - Cheng,Andrew K
AU  - Fordyce,Marshall W
AU  - McCallister,Scott
TI  - Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
SN  - 1474-547X
PY  - 2015///0716
KW  - Adenine
KW  - administration & dosage
KW  - Adult
KW  - Alanine
KW  - Anti-HIV Agents
KW  - adverse effects
KW  - Arthralgia
KW  - chemically induced
KW  - Bone Density
KW  - drug effects
KW  - CD4 Lymphocyte Count
KW  - Carbamates
KW  - Cobicistat
KW  - Deoxycytidine
KW  - Double-Blind Method
KW  - Drug Combinations
KW  - Emtricitabine
KW  - Female
KW  - HIV Infections
KW  - drug therapy
KW  - Headache
KW  - Humans
KW  - Kidney
KW  - Male
KW  - Nausea
KW  - Organophosphonates
KW  - Quinolones
KW  - Respiration Disorders
KW  - Sleep Initiation and Maintenance Disorders
KW  - Tenofovir
KW  - Thiazoles
KW  - Treatment Outcome
KW  - Viral Load
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S0140-6736(15)60616-X
ER  -